National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
NCT Number: NCT02473757
Background:
- Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects. NIH is required to try to contact people who have been treated with gene therapy at least annually for up to 15 years. This is to see if they have had any bad side effects. This trial does not include any therapy and is only for patients previously treated on gene-therapy trials at the NCI Surgery Branch who are no longer enrolled on their original gene therapy clinical trial.
Objective:
- To collect of long-term follow-up data on people who have been in gene transfer studies. This follow-up is required by regulators.
Eligibility:
- People age 18 and older who have been in a previous NCI Surgery Branch gene therapy research study.
Design:
* After they get the genetically modified cells, participants will: * Have blood drawn 3, 6, and 12 months later. * Have an annual clinic visit for the next 4 years. They will have a physical exam. They will answer questions about any signs of neurological, autoimmune, or blood disorders, or any new cancers. Blood may be drawn. * Be called or emailed annually for the next 10 years. They will answer health questions. Blood samples may need to be taken. * Participants will be asked for their current address and phone number. They will also be asked for the address and phone number of 1 or 2 people who will know their whereabouts. One of these should be a family member if possible, * At the time of the participant s death, researchers will request permission from their family for an autopsy.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bethesda, Maryland, 20892, United States
Background:
-The National Cancer Institute Surgery Branch (NCI-SB) Branch investigator conducts clinical trials utilizing gene transfer. The current U.S. Food and Drug Administration (FDA) requirements for long term follow up may be up to fifteen years for some products. As this time period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow up of these subjects
Objectives:
-To facilitate collection of long term, follow up information on subjects who have participated in gene transfer studies as required by the U.S. Food and Drug Administration and other regulatory groups
Eligibility:
-Enrollment on a CAR T-cell treatment protocol for gene therapy.
Design:
-Patients will undergo physical exams; laboratory evaluation or phone follow up as required by the treatment protocol and/or as clinically indicated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Time frame: 15 years
List of long time adverse event frequency after Gene therapy drug
National Cancer Institute (NCI)
Nih
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07255898
Blood Protein Disorders, Cardiovascular Diseases
Chengdu, Sichuan, China
View Trial DetailsNCT06296368
Blood Cancers, Blood Protein Disorders
Chapel Hill, North Carolina, United States
View Trial DetailsNCT01345019
Blood Protein Disorders, Bone Diseases
Tucson, Arizona, United States
View Trial DetailsNCT03852407
Acute Lymphoid Leukemia in Remission, Acute Myeloid Leukemia in Remission
Antwerp, Belgium
View Trial Details